CN103800356B - 一种治疗小细胞癌的药物组合物及其应用 - Google Patents
一种治疗小细胞癌的药物组合物及其应用 Download PDFInfo
- Publication number
- CN103800356B CN103800356B CN201410070973.2A CN201410070973A CN103800356B CN 103800356 B CN103800356 B CN 103800356B CN 201410070973 A CN201410070973 A CN 201410070973A CN 103800356 B CN103800356 B CN 103800356B
- Authority
- CN
- China
- Prior art keywords
- etoposide
- chimonin
- pharmaceutical composition
- small cell
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 208000000649 Small Cell Carcinoma Diseases 0.000 title abstract description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims abstract description 30
- 229960005420 Etoposide Drugs 0.000 claims abstract description 30
- 239000009633 chimonin Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 12
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000001629 suppression Effects 0.000 abstract description 6
- 210000004881 tumor cells Anatomy 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N Mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 230000035521 G2 Phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 206010025482 Malaise Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000036191 S Phase Effects 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940043357 mangiferin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 210000001142 Back Anatomy 0.000 description 1
- 241000596154 Belamcanda Species 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 229940084030 CARBOXYMETHYLCELLULOSE CALCIUM Drugs 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 241001093152 Mangifera Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000000143 Urethritis Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003882 argentaffin cell Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical compound C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930013686 lignans Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
药物浓度(微米/L) | 细胞生长抑制率(%) | CI值 |
芒果苷(1微米/L) | 2.4±0.2 | |
芒果苷(2微米/L) | 3.1±0.3 | |
芒果苷(40微米/L) | 7.3±0.5 | |
芒果苷(80微米/L) | 10.5±0.7 | |
芒果苷(160微米/L) | 13.5±0.9 | |
依托泊苷(1微米/L) | 13.2±1.1 | |
依托泊苷(2微米/L) | 26.3±2.0 | |
依托泊苷(6微米/L) | 37.9±1.5 | |
依托泊苷(10微米/L) | 53.8±2.2 | |
依托泊苷(16微米/L) | 67.2±2.4 | |
芒果苷(20微米/L)+依托泊苷(1微米/L) | 37.6±3.4 | 0.261 |
芒果苷(20微米/L)依托泊苷(2微米/L) | 40.3±3.6 | 0.44 |
芒果苷(20微米/L)依托泊苷(4微米/L) | 56.1±2.5 | 0.417 |
芒果苷(40微米/L)依托泊苷(6微米/L) | 79.2±3.7 | 0.12 |
芒果苷(40微米/L)依托泊苷(2微米/L) | 48.3±3.9 | 0.316 |
组别 | CR | PR | SD | PD |
治疗组 | 5 | 23 | 11 | 1 |
对照组 | 1 | 15 | 17 | 7 |
骨髓抑制 | 0 | I | II | III | IV |
治疗组 | 15 | 9 | 8 | 5 | 3 |
对照组 | 8 | 9 | 6 | 11 | 6 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410070973.2A CN103800356B (zh) | 2014-02-28 | 一种治疗小细胞癌的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410070973.2A CN103800356B (zh) | 2014-02-28 | 一种治疗小细胞癌的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103800356A CN103800356A (zh) | 2014-05-21 |
CN103800356B true CN103800356B (zh) | 2016-11-30 |
Family
ID=
Non-Patent Citations (2)
Title |
---|
Mangiferin activates Nrf2-antioxidant response element signaling without reducing the sensitivity to etoposide of human myeloid leukemia cells in vitro;Ben-ping ZHANG, et al,;《Acta Pharmacologica Sinica》;20131230;摘要 * |
芒果苷药理活性研究进展;任晓光等;《中成药》;20110531;第33卷(第5期);第860-863页 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5057987B2 (ja) | 薬草組成物phy906及びその化学療法における使用 | |
CN105769891A (zh) | 低极性稀有人参皂苷混合物及其用途 | |
CN106822905A (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
CN102526427B (zh) | 治疗胃肠疾病的中药组合物及质量检测方法 | |
CN103263433A (zh) | 6-姜烯酚增强胰腺癌对吉西他滨化疗敏感性及其复方药物 | |
CN101926815B (zh) | 一种治疗类风湿关节炎和湿疹的芍药苷和甘草次酸组合物及其制备方法与应用 | |
CN102579425A (zh) | 鸡血藤提取物及其应用和异甘草素的新用途 | |
CN100508986C (zh) | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 | |
CN103800356B (zh) | 一种治疗小细胞癌的药物组合物及其应用 | |
CN105147696A (zh) | 联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法 | |
CN107349210A (zh) | 具有α‑淀粉酶协同抑制活性的组合物 | |
CN101152193B (zh) | 1,3,4-三-O-没食子酰基-6-O-咖啡酰基-β-D-吡喃葡萄糖在制备抗肿瘤药物中的应用 | |
CN100502867C (zh) | 青藤碱用于抗肿瘤药物的制备 | |
CN103800356A (zh) | 一种治疗小细胞癌的药物组合物及其应用 | |
CN103271907B (zh) | 一种小檗碱和二甲双胍的口服药物组合物及其制备方法 | |
CN102716128A (zh) | 一种治疗哮喘的药用组合物 | |
CN100443081C (zh) | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 | |
CN100420442C (zh) | 协同抗肿瘤的野黄芩甙元和黄芩甙药物组合物 | |
CN100546621C (zh) | 一种已知药物的新用途 | |
CN100411650C (zh) | 一种治疗痹症的复方胶囊 | |
CN115381954B (zh) | 一种用于治疗骨肉瘤的联合用药物 | |
CN1879615B (zh) | 抗肿瘤的协同药物组合物 | |
CN102688330A (zh) | 一种生物中药药膜及其制备方法 | |
CN100482245C (zh) | 板蓝根和黄芩苷的药物组合物 | |
CN101590109B (zh) | 一种治疗老年骨质疏松性腰痛的复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Wu Inventor after: Xu Yan Inventor after: Chen Qian Inventor after: Li Chunyan Inventor before: Sun Zheyu Inventor before: Wang Ping Inventor before: Yang Hongxia Inventor before: Wang Luanqiu Inventor before: Han Shuhong |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20160930 Address after: Qingdao City, Shandong province 266000 four Road No. 127 Applicant after: QINGDAO TUMOUR HOSPITAL Address before: North Helen Road No. 24 805 Applicant before: Sun Zheyu |
|
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20170228 |